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Summary
The survival of T lymphocytes is tightly controlled during development. Here, we show that
Bcl-x,, a protein homologue of Bcl-2, is highly regulated in the thymus in a pattern different
than that ofBcl-2. The maximum expression was in CD4+CD8+ thymocytes, a developmental
stage where Bcl-2 is downregulated. To assess the role of Bcl-x, in thymocyte apoptosis, we
generated mice overexpressing an EN,-bcl-x transgene within the T cell compartment. Consti-
tutive expression of BC'-XL resulted in accumulation of thymocytes and mature T cells in lym-
phoid organs. Thymocytes overexpressing BC'-xL exhibited increased viability in vitro and
were resistant to apoptosis induced by different signals, including glucocorticoid, y irradiation,
calcium ionophore, and CD3 cross-linking. However, BC'-xL was unable to block clonal dele-
tion of thymocytes reactive with self-superantigens or H-Y antigen. These studies demonstrate
that Bcl-2 and BC'-XL, two functionally related proteins, are regulated independently during T
cell development. In contrast to Bcl-2, which has been implicated in the maintenance of ma-
ture T cells, BC'-xL appears to provide a survival signal for the maintenance of more immature
CD4+ CD8+ thymocytes before positive selection.
Lymphoid development is regulated by an array of cellu-
lar processes that include proliferation, differentiation,
and cell death. Cell death is accomplished by apoptosis, a
morphologically defined process that is widespread during
embryogenesis and postnatal development (1) . Apoptosis
serves to ensure the selection ofappropriate lymphoid pop-
ulations during thymic development and to dampen the
immune response in peripheral tissues (2, 3). It is estimated
that as many as 97% ofthe T cell precursors die during thy-
mic development through apoptosis (4) . The assembly of
TCR genes is largely a random process resulting in a large
fraction of developing T cells that fail to assemble func-
tional TCRs and are thought to be eliminated by apoptosis
(4). Developing CD4+CD8+ thymocytes that express
functional TCRs are further selected by positive and nega-
tive events involving the interaction of TCRs with pep-
tides complexed with MHC molecules (5, 6). Negative se-
lection is a major mechanism to establish self-tolerance.
Specifically, CD4+CD8+ thymocytes that bear TCRs with
high affinity for self-peptide-MHC complexes are elimi-
nated by apoptosis (2, 3, 6) . Developing T cells that suc-
cessfully complete intrathymic selection processes are ex-
ported to the periphery as mature CD4+ or CD8+ T
lymphocytes.
The recognition of antigenic peptides by TCRs in the
context of MHC molecules is the fundamental event shap-
ing the fate of developing T cells. A variety of stimuli and
cellular interactions can trigger the death of T cells by acti-
vating the apoptotic process. These include deprivation of
essential growth factors, signaling through cell surface re-
ceptors other than TCRs, and exposure to agents such as
glucocorticoids, calcium ionophore, or genotoxic drugs
(1) . The mechanisms that mediate and regulate apoptosis
are still poorly understood, but it is thought that cell death
is controlled by a genetic program that is induced within
the dying cell (1, 7) . There is increasing evidence that a
major function of the death program is to activate proteins
that act as effectors of the apoptotic mechanism (8, 9) .
However, apoptosis is further regulated by a set of genes
that function as repressors of cell death (8) .
The bcl-2 protooncogene was the first member of an ex-
panding family of genes that suppress the apoptotic mecha-
nism (10). Constitutive expression of bd-2 in lymphoid
cells prevents or delays apoptosis induced by multiple stim-
uli (11-14). A role for Bcl-2 in the selection of T lympho-
cytes was suggested by its highly restricted cellular distribu-
tion within the thymus (15-18). Recent evidence suggest
that Bcl-2 plays a role in positive selection in the thymus
(19-22) . The ability of Bcl-2 to influence negative selec-
tion in the thymus is controversial. Some investigators have
found that enforced expression of bd-2 was inefficient in
protecting self-reactive thymocytes from clonal deletion
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deletion but not self-tolerance by bcl-2 overexpression (14,
19,23) .
Mice deficient in Bcl-2 exhibit normal maturation of
both B and T cell lineages, indicating that Bcl-2 is not es-
sential for lymphoid development (24, 25). A plausible ex-
planation is that proteins other than Bcl-2 can function as
survival signals during the selection and maintenance of T
lymphocytes. A candidate is BC'-XL, a product of bcl-x, an-
other gene of the bcl-2 family (26, 27). Like Bcl-2, Bcl-xL
localizes to mitochondrial membranes and perinuclear en-
velope (26) and inhibits the apoptotic death of hematopoi-
etic cell lines after growth factor withdrawal (27). In mice,
bcl-xL is the dominant bcl-x mRNA expressed in embryonic
andpostnatal tissues, including the thymus (26, 28). Recent
analyses of chimeric mice with a disrupted mutation of bcl-x
demonstrate a major role for bcl-x during lymphoid devel-
opment (29) . However, the biological basis for the altered
phenotype observed during T cell maturation in Bcl-x-
deficient chimeric mice remains undetermined.
In these studies, we determined the distribution of the
endogenous Bc1-xL in thymocytes and T cells and exam-
ined the effect of constitutive expression of bcl-x, in the T
cell lineage. We showed that thymocytes and peripheral T
cells from transgenec ENt,-bcl-xL mice accumulated in the
animal and exhibited prolonged survival in vitro. Further-
more, thymocytes overexpressing bd-xL exhibited increased
survival after exposure to a diverse array of death-promot-
ing stimuli that include glucorticoid hormones, ionizing ra-
diation, calcium ionophore, and activation through CD3
molecules. In addition, we demonstrated that tolerance was
maintained despite constitutive bd-xL expression since dele-
tion ofself-reactive lymphocytes was unaffected in the thy-
mus and peripheral lymphoid organs. Finally, we showed
that Bcl-2 and Bcl-x, proteins exhibited discordant cellular
distribution in the thymus and peripheral T cells. The im-
plications of these findings for physiological pathways of T
cell selection and survival are discussed.
Materials and Methods
Mice andInjections.
￿
C57BL/6, BALE/c, CBA/Ca and CBA/J
mice were obtained from the Jackson Laboratory (Bar Harbor,
ME). Animals used for these studies were between 8 and 12 wk
ofage (unless otherwise indicated) . C57BL/6 mice expressing the
ot and [3 transgenes for the H-Y TCR were a gift of Dr. Harald
von Boehmer (Basel Institute for Immunology, Basel, Switzer-
land) (30) . They were bred and maintained in a pathogen-free
environment at the University of Michigan. Glucocorticoids
were administered by injection of 2 mg i.p. of dexamethasone
(American Regent Laboratories, Inc., Shirley, NY). Hamster
anti-mouse CD3 (clone 145-2C11 ; 100 1Lg) or anti-DNP (clone
UC8-1139; 100 Rg), provided by Dr. R. Miller (University of
Michigan), were injected intraperitoneally.
Construction of the SV40-Eht,-bcl-xL Transgene and Generation of
Transgenic Mice. To target bcl-x, to the lymphoid compartment,
the human bd-xL cDNA was cloned under the regulatory control
of the SV40 promoter and immunoglobulin heavy chain en-
hancer using a SV40-EH cassette (31). The 2.4-kb fragment con-
taining the SV40-EH-bcl-xL insert was microinjected into F2
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hybrid zygotes from (C57BL/6 X SJL/J)Fl parents at a concen-
tration of 2-3 ng/lt.l. After overnight incubation, the eggs that
survived to a two-cell stage were transferred to day 0.5 postcoi-
tum pseudopregnant CS-1 females. 3 wk after birth, genomic
DNA was prepared from tail tissue, and the incorporation of the
human bcl-x, transgene was assessed by dot blot analysis or PCR
as previously described (27).
Cell Preparations. Murine lymphoid organs were placed in
sterile PBS, and the tissue was disrupted with the tip of the
plunger ofa sterile 1-ml syringe. Cells were washed in cold PBS
and centrifuged three times at 400 g for 5 min to remove cellular
aggregates. Single-cell preparations were counted and assessed for
viability by trypan blue exclusion. The cells were cultured at
37°C in RPMI supplemented with 2 MM L-glutamine, 10-5 M
2-ME, and 10% heat-inactivated FCS (Hyclone Laboratories
Inc., Logan, UT). In some experiments, cells were incubated
with dexamethasone (American Regent Laboratories, Inc.) or ion-
omycine (Sigma Chemical Co., St. Louis, MO) or irradiated before
culture by exposure to a Co source at 250 rad. Cell proliferation
in triplicate cultures was determined by adding Con A (10 p,g/
ml) to 4 X 105 lymphocytes in 96-well microplates (Falcon Plas-
tics, Cockeysville, MD). After 3 d of culture, 1 ft,Ci of [3H]thymi-
dine (Amersham Corp., Arlington Heights, IL) was added, cells
were harvested, and [3H]thymidine incorporation was measured in
ascintillation counter (Beckman Instruments, Inc., Fullerton, CA).
Antibodies.
￿
FITC-labeled anti-CD4 (clone H129.19) and PE-
conjugated anti-CD8 (clone 53-6.7) mAbs were purchased from
GIBCO BRL (Gaithersburg, MD). The following antibodies
were obtained from PharMingen (San Diego, CA): biotinylated
anti-CD4 (clone RM-4-5), biotinylated anti-CD3-e (clone 145-
2C11), biotinylated and PE-conjugated anti-CD45R (13220)
(clone RA3-6132), PE-conjugated CD24 (heat stable antigen)
(clone M1/69), FITC-labeled anti-IgM (clone R6-60.2), FITC-
labeled anti-CD43 (leukosialin) (clone S7), FITC-labeled anti-
VR2 TCR (clone 1320.6), FITC-labeled anti-V[36 TCR (clone
RR4-7), FITC-labeled anti-V[38.1, 8.2 TCR (clone MR5-2),
FITC-labeled anti-V[311 TCR (clone RR3-15). The streptavi-
din RED670 reagent waspurchased from GIBCO BRL.
Flow Cytometric Analysis.
￿
106 cells were incubated with the
indicated antibodies in 100 ILI of PBS with 1% BSA for 30 min
on ice and washed twice with PBS/1% BSA. When indicated, 25
LLI of streptavidin RED670 was used for three-color analysis.
Cells were analyzed with a FACScane flow cytometer anda min-
imum of3 X 10" events per sample were counted using Lysys II
software (Becton Dickinson & Co., Mountain View, CA). Anal-
ysis ofBcl-x expression by flow cytometry was performed as pre-
viously described forBcl-2 (32), using a mouse IgG2b anti-Bcl-x
mAb (Transduction Lab., Lexington, KY), followed by a biotiny-
lated goat anti-mouse IgG2b (CALTAG Laboratories, South San
Francisco, CA). Apoptosis levels in thymocytes were assessed by
propidium iodide (PI)' staining as previously described (33).
Briefly, a pellet of 5 X 105 cells was resuspended in 600 N.l of
HZO containing 50 lLg/ml of PI, 0.1% Triton X-100 (Sigma
Chemical Co.), and 0.1% sodium citrate and then incubated at
4°C overnight in the dark. Cells were analyzed by flow cytometry.
Western Blotting Analysis.
￿
Bcl-xL protein expression was de-
termined by Western blotting as previously described (32) . Briefly,
proteins were transferred to nitrocellulose membranes by electro-
phoresis and then incubated at 4°C overnight with a rabbit anti-
'Abbreviations used in this paper: HRP, horseradish peroxidase; PI, propid-
ium iodide; TBS, Tris-buffered saline.
bd-xL Expression Is Regulated in the Thymus andBlocks ApoptosisBcl-x polyclonal serum (provided by Dr. Craig Thompson, Uni-
versity of Chicago, Chicago, IL) diluted 1:500 in 1 .5% milk Tris-
buffered saline (TBS) with 30 pd of normal goat serum (Sigma
Chemical Co.) or with a mouse anti-R-tubulin antibody (Sigma
Chemical Co.) at 1 Rg/ml diluted in 1.5% milk-TBS. After five
washes in TBS with 0.05% Tween 20, the membrane was incu-
bated for 1 h at room temperature with goat anti-rabbit antibody
conjugated to horseradish peroxidase (Jackson ImmunoResearch
Laboratories, Inc., West Grove, PA) diluted 1 :50,000 in 1 .5%1
milk-TBS or with goat anti-mouse antibody conjugated to HRP
(Jackson ImmunoResearch Laboratories) diluted 1:25,000 in
1 .5% milk-TBS. Bound antibody was detected by chemilumines-
cence using the ECL Western Blot kit (Amersham Corp.).
Results
Discordant Regulation ofBcl-x and Bcl-2 during T Cell De-
velopment. In thymic tissue of normal mice, Bcl-xL is the
only Bcl-x protein detected by Western blot analysis using
polyclonal antisera (34) . To examine the expression of the
endogenous Bcl-xL protein in subsets of thymocytes, cells
were labeled with anti-Bcl-x mAb, anti-CD4, and anti-
CD8 antibodies. The expression of Bcl-xL was low in
CD4 - CD8- cells, increased in CD4+CD8+ immature thy-
mocytes, and downregulated in more mature CD4+CD8 -
or CD8+CD4- thymocytes (Fig. 1) . Furthermore, the
BC'-xL protein was not detected in unstimulated peripheral
CD4+ or CD8+ T cells (Fig. 1). This difference in BC'-xL
expression was quantified by calculating the ratio of mean
channel fluorescence of Bcl-xL and that of control Ig in
each subpopulation of thymocytes and peripheral T cells.
The mean channel fluorescence ratio for CD4-CD8-,
CD4+ CD8- , and CD4- CD8+ thymocytes was similar
(1 .9 ± 0.2, 2.0 ± 0 .4 and 2.0 ± 0.3, respectively), in-
creased for CD4+ CD8+ (4.4 ± 0.5), and decreased for pe-
ripheral CD4+ and CD8+ T cells (1 .0 ± 0.1). Thus, the
expression of Bcl-x, is tightly controlled during T cell de-
velopment and differs significantly from that previously ob-
served for Bcl-2 (15-18) .
Generation of Transgenic Mice Expressing Deregulated bd-xL
in Thymocytes and Peripheral T Cells. We developed a
transgenic mouse model overexpressing Bcl-x, to assess its
effects on T cell development. The bcl-xL transgene was
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under the control of the IgH chain enhancer, which is
known to target genes to lymphoid cells (31, 35, and Fig. 2
A). Seven founders expressing Bcl-x, in lymphoid tissues
were identified and used to establish transgenic lines. Each
line was assessed for expression of BC'-xL protein by West-
ern blot analysis using a polyclonal antibody reactive with
the murine and human Bcl-x proteins. Two lines (bcl-x-169
and bcl-x-86) that exhibited restricted expression of the
bcl-xL transgene to the T cell compartment were further
characterized. Targeted expression of transgenes driven by
the SV40 promoter and IgH enhancer to the T lineage has
been reported in all major thymocyte subsets and periph-
eral T cells (14, 36). As shown in Fig. 2 B, the BC'-xL pro-
tein was overexpressed in the thymus of bcl-x-169 (five-
fold) and bcl-x-86 mice (two fold) when compared with the
endogenous levels of Bcl-x, in normal thymocytes. Quan-
tification was obtained by densitometry scanning and nor-
malized to the reference gene R-tubulin. Moreover, BC'-xL
was not detected in the spleen and lymph nodes of normal
mice but was expressed in bcl-x-transgenic animals (Fig. 2
B) . Lastly, the bd-xL transgene was not found in purified
populations of splenic B cells and in several nonlymphoid
organs, including brain, liver, kidney, and lung, as deter-
mined by comparison to endogenous levels of Bcl-xL ob-
served in control mice (data not shown) .
Constitutive Expression of Bcl-xL Leads to Accumulation of
Thymocytes and Peripheral T Cells. The expression of the
bd-xL transgene in the thymus increased the number oftotal
thymocytes. Table 1 shows the results obtained for trans-
genic mice compared with control littermates. In bcl-x-169,
the total number of thymocytes increased by 46% (41 .2 X
106 vs. 60 X 106 in transgenic mice), and the three major
subsets of thymocytes (CD4+CD8+, CD4+CD8-, and
CD4-CD8+) were augmented over control littermates . In
bcl-x-86 mice whose thymocytes expressed less Bcl-xL pro-
tein than bcl-x-169 (Fig. 2 B), the total number of thy-
mocytes at 6 wk was similar to nontransgenic littermates
(data not shown) . However, by 10 wk of age, the total
number of thymocytes increased by 58% (from 43 X 106 in
control to 68 X 106 in transgenic mice) and displayed a
slight increase in all thymocyte subsets when compared
with the effects observed in bcl-x-169 . Thus, constitutive
SPLEEN
Figure 1 .
￿
Flow cytometric analysis of murine
CD4+
￿
endogenous Bcl-x expression. Thymocytes and
spleen cells from 8-wk-old C57BL/6 mice were la-
beled with FITC-conjugated anti-CD4 and PE-
conjugated anti-CD8 antibodies. Cells were fixed
with PBS containing 2% paraformaldehyde, labeled
with anti-Bcl-x mAb or isotype-matched control
antibody, and analyzed by flow cytometry. BC'-xL
expression was assessed in different T cell popula-
tions. Data are presented as a frequency histogram
with fluorescence intensity on the horizontal axis
and relative cell number on the vertical axis. a and b
represent background level and BC'-xL expression,
respectively. For splenic CD4+ and CD8+ T cells,
histograms representing background and BC'- xL
staining overlap. Results are representative of three
different experiments.Figure 2 . EN.-bcl-xL transgene construct and Westen blot analysis of
Bcl-xL expression. (A) A 0.75-kb cDNA fragment containing the coding
region ofhuman bcl-xLwas inserted into the EcoRI site ofthe ER-SV40
cassette (14) . EN, is the immunoglobulin heavy enhancer and SV40 the
early SV40 promoter . (B) Expression of Bcl-xL was assessed by Western
blot analysis with a polyclonal anti-Bcl-x antibody followed by goat anti-
rabbit serum conjugated to HRP . Lysates from 10 6 cells were loaded in
each lane . In the left lane, lysate from FL-5.12 cells transfected with the
murine bcl-xL cDNA (26) is shown as a positive control indicated as Bcl-
XL. As a control, expression of (3-tubulin was also assessed with a mouse
anti-l3-tubulin antibody followed by goat anti-mouse serum conjugated
to HRP .
Bcl-xL expression during T cell development resulted in
uniform accumulation of thymocytes, and its effect on thy-
mocytes correlated with the amount ofBcl-xL expressed in
the thymus.
Table 1.
￿
Thymocyte Populations in bcl-x-169-and bcl-x-86-transgenic Mice
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The size of the peripheral T cell pool was increased by
deregulated bcl-x,. The total number of lymphocytes in
bcl-x-169 mice increased in lymph nodes (from 10 X 106 in
control littermates to 29 X 106 ) and spleen (from 61 X 10 6
to 85 X 106) (Table 2) . The increase in lymphoid cells re-
flected an accumulation of both CD4 and CD8 mature T
cells . The increase in T cells was more pronounced in
lymph nodes (5.5-fold) than in spleen (2-fold) . Similar ef-
fects on peripheralT cells were observed in bcl-x-86 mice .
However, the accumulation of mature T cell subpopula-
tions was less pronounced in bcl-x-86 than in bcl-x-169
mice . Whereas the percentage ofB cells in peripheral lym-
phoid organs fell drastically, the absolute number ofB cells
did not differ significantly between transgenic and control
mice . Furthermore, different subsets of developing and ma-
ture B cells were unaltered in transgenic mice, indicating
that the phenotypic changes mirrored the pattern of trans-
gene expression (data not shown) . Thus, in contrast to Bcl-2
(13, 14), constitutive Bcl-xL expression in theT cell lineage
increases the number of thymocytes and mature CD4 and
CD8T cells in peripheral organs .
Bcl-xL Increases the Survival of Thymocytes and Peripheral T
Cells In Vitro . To assess the effect of bd-xL on their sur-
vival, thymocytes from bcl-x,:transgenic and control litter-
mates were cultured in RPMl medium supplemented with
10% FCS, and their viability was assessed by trypan blue
exclusion . There was an improved survival of transgenic
thymocytes compared with control thymocytes . By day 6
of culture, 50% of thymocytes from bcl-x-169 and 36% from
bcl-x-86 mice were still viable, whereas <5% of the control
thymocytes survived (Fig . 3) . Similarly, splenicT cells from
bcl-x-transgenic mice exhibited increased survival com-
bd -xL Expression Is Regulated in the Thymus and Blocks Apoptosis
*Results were obtained by two-color flow cytometric analysis of thymocytes simultaneously labeled with FITC-conjugated anti-CD4 and PE-con-
jugated anti-CD8 antibodies . Values shown represent the mean ± SD for 10 animals .
*Differences between transgenic and control littermates were statistically significant (p <0.01) as assessed by Student's t test . bcl-x-169-transgenic and
control littermates were 6 wk old . bd-x-86-transgenic and control littermates were 10 wk old .
n (X
Transgenic mice
106)
Control
n (X 10 6 )
littermates
%
bcl-x-169
Total cells 60.0 ± 2.0*$ 41 .2 ± 2 .1$
CD4-CD8- 1 .7 -!- 0.2 2.9 ± 0.3 1 .1 ± 0.5 2.8 ± 0.4
CD4+CD8+ 47.9 ± 2.4$ 79.8 ± 1 .3$ 36.0 ± 1 .9$ 87.5 ± 0.7$
CD4+CD8- 4.6 ± 0.4$ 7.6 ± 0.3$ 1.8±0.3$ 4.3±0.5$
CD4-CD8+ 2.1 -!- 0.1$ 3.5 -} 0.1$ 0.6±0.1$ 1.4±0.1$
bcl-x-86
Total cells 68.0 ± 3.1$ 43.0 ± 2 .2$
CD4-CD8- 1 .4 ± 0.4 2.0 ± 0.5 1 .2 ± 0.5 2.7 ± 0.9
CD4+CD8+ 56.6 - 2.3$ 83.3 ± 0.7 36 .1 ± 1 .4$ 84.0 - 0.6
CD4+CD8- 3.9 ± 0.8$ 5.7 ± 1.0 2.0 ± 0.9$ 4.6 ± 0.9
CD4-CD8+ 1 .2 ± 0.1$ 1 .7 ± 0.2 0.7±0.1$ 1.6±0 .1Table 2.
￿
Lymphoid Populations in Lymph Nodes and Spleen ofbcl-x-169-and bcl-86-transgenic Mice
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pared with T cells from control littermates (data not shown).
However, the capacity ofboth transgenic and control splenic
T cells to proliferate in response to Con A in culture was
virtually identical (data not shown).
Bd-xL Protects Thymocytes against Dexamethasone, y Irradia-
tion, and Calcium Ionophore-induced Cell Death In Vitro. Glu-
cocorticoid hormones are known to cause a rapid depletion
of thymocytes by apoptosis (37) . To evaluate whether bcl-
xL inhibits DNA fragmentation associated with glucorti-
Figure 3 .
￿
Expression of the trans-
gene bd-xL increases thymocyte via-
bility in vitro. Thymocytes from
transgenic bcl-x-169 (solid squares)
and bcl-x-86 (solid circles) and their
respective control littermates (open
squares and open circles) were cultured
in 96-well flat-bottomed plates at
106 cells/ml in RPMI with 10%
FCS. From day 1 to day 6, viability
ofthymocytes was assessed by trypan
blue exclusion. All data points repre-
sent the mean of triplicate cultures
-I - SD for three independent experi-
ments.
*Results were obtained by three-color flow cytometric analysis. Cells from spleen and inguinal and axillary lymph nodes were simultaneously la-
beled with FITC-conjugated anti-CD4, PE-conjugated anti-CD8, and biotinylated anti-13220 antibodies. Values shown represent the mean ± SD
for
$Differences between transgenic and control littermates were statistically different (p <0.01) as assessed by the Student's t test.
coid-induced apoptosis, thymocytes were treated with 0.1
p,M of dexamethasone in culture for up to 18 h . Flow cy-
tometric analysis revealed that dexamethasone-treated thy-
mocytes displayed a sub-Go DNA peak, which is known to
correspond to fragmented DNA in thymocytes (38) . At 6 h,
only 10% ofthymocytes from bcl-x-169 mice were apoptotic
in the presence of dexamethasone compared with 75% of
control thymocytes. At 18 h, 40% of the dexamethasone-
treated thymocytes from bcl-x-169 mice contained frag-
mented DNA as assessed by staining of nuclei with PI ver-
sus 95% of dexamethasone-nontransgenic thymocytes (Fig.
4 A) . A lesser level of protection against dexamethasone-
induced DNA fragmentation was observed for thymocytes
from bcl-x-86 at 6 and 18 h of culture (Fig. 4 A) .
Because glucocorticoids and irradiation appear to induce
thymocyte apoptosis in part by different pathways (9), the
ability of bd-xL to protect against irradiation-induced cell
death was evaluated in thymocyte cultures. At a dose of
250 rod, >35% and 80% of control thymocytes displayed
fragmented DNA at 6 and 18 h, respectively, after irradia-
tion (Fig. 4 B). However, thymocytes from bcl-x-169 mice
were remarkably resistant to irradiation (Fig. 4 B). Thy-
mocytes from bcl-x-86 mice were also more resistant to ir-
radiation than cells from control littermates (Fig. 4 B) .
n (X
Transgenic mice
106)
Control
n (X 106)
littermates
bcl-x-169
Lymph node 29.0 ± 4.0*$ 10.0 ± 1.5t
CD4+ 14.2 ± 3.0$ 48.8 ± 3.7t 2.3 ± 0.3t 22.6 ± 0.3t
CD8+ 7.1 ± 0.5t 24.5 ± 0.3t 1.6±0.3t 15.5±0.5t
13220+ 5.8 ± 1.6 3.8 ± 0.6 38.1 ± 0.2t
Spleen 85.0 ± 9.9t 61 .0 ± 8.5t
CD4+ 21.0 ± 3.0$ 25.4 ± 0.7t 10.3 ± 2.0$ 16.9 -} 1.0$
CD8+ 10.2 ± 1.0t 12.0 ± 0.1t 5.8±1 .1t 9.5±0.6t
13220+ 37.5 ± 9.9 44.1 ± 7.4 32.9±5.5 54.0±3.5
bcl-x-86
Lymph node 20.0 ± 2.0$ 11 .0 ± 2.0$
CD4+ 6.9 ± 1.0t 34.7 ± 0.7t 2.1±0.3t 18.9 - ±0.2$
CD8+ 5.6 ± 0.4t 28.2 ± 2.2t 1.8±0.5$ 16.4±1 .8t
13220+ 3.7 ± 0.4 18.3 ± 4.Ot 4.7±0.6 43.0±3 .Ot
Spleen 80.0 ± 3.0t 61 .0 ± 1.Ot
CD4+ 16.1 ± 1.5t 20.1 ± 0.9t 9.0±2.Ot 14.7±1 .8t
CD8+ 9.8 ± 1.0 12.3 ± 1.4t 4.4 ± 1.1t 7.2 ± 1.6t
13220+ 35.1 ± 4.0 43.9 ± 6.1t 39 .2 ± 1.3 64.3 ± 10te
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Figure 4.
￿
BC'-xL protects thymocytes against dexamethasone- and -i ir-
radiation-induced apoptosis in vitro. (A) Thymocytes from transgenic bcl-
x-169 (squares), bcl-x-86 (circles), and control mice (triangles) were cultured
at 106 cells/ml (24-well plates) in the presence (open symbols) or absence
(solid symbols) of 1 [LM ofdexamethasone. At 0, 3, 6, and 18 h, cells were
fixed with paraformaldehyde, penneabilized with Triton X-100, and as-
sessed for nuclear DNA content by PI staining. Cell were analyzed by
flow cytometry. Data represent mean ± SEM of apoptotic cells in tripli-
cate cultures for three independent experiments. (B) Thymocytes from
mice transgenic for bcl-x-169 (squares), bcl-x-86 (circles), and control mice
(triangles) were 'y irradiated (open symbols) or not (solid symbols) at 250 rod
and then cultured in vitro for 18 h at 106 cells/ml in 24-well plates. The
percentage ofapoptosis at 0, 3, 6, and 18 h was determined by analysis of
the nuclear DNA content by PI staining. Data represent mean ± SD of
apoptotic cells in triplicate cultures for three independent experiments.
In addition, thymocytes from bcl-x-transgenic mice were
resistant to death induced by calcium ionophore. After 10 h
of exposure to 2 Ntg/ml of ionomycin, 88 ± 5% of the
control thymocytes were apoptotic versus 9 ± 2% of the
thymocytes from bcl-x-169 mice.
Bd-xL Protects Thymocytes against Dexamethasone-induced
Cell Death In Vivo. To assess the effects of bcl-x, on thy-
mocyte survival in vivo, bcl-x-169-transgenic and control
littermates received 2 mg i.p. of dexamethasone by injec-
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tion, and thymocyte populations were examined 48 h later
by flow cytometric analysis. Dexamethasone treatment elim-
inated 70 ± 10% of total thymocytes from control mice
compared with PBS-treated animals (from 45 X 106 to 14 X
106). In contrast, transgenic thymocytes were markedly
protected from dexamethasone, with a decrease of only 15 -,--
3% (from 61 X 106 to 51 X 106) . Further analysis revealed
that CD4+CD8+ thymocytes from control mice were al-
most entirely eliminated by dexamethasone, whereas 72% of
this population remained viable in bcl-x-transgenic animals
(Fig. 5). In paralleled experiments, treatment with dexa-
methasone deleted equally B22010"'IgM- B cells from trans-
genic and control animals, demonstrating that the protec-
tion conferred by bcl-xL was lineage specific and mirrored
transgene expression (Fig. 5) .
Bcl-xL Protects against Anti-CD3-induced Apoptosis In Vivo.
Triggering of CD4+CD8+ thymocytes with anti-CM in-
duces apoptosis in vitro and in vivo (2, 39). To assess Bcl-
xL ability to block anti-CD3-induced apoptosis, transgenic
mice and control littermates were injected with anti-CD3,
and their thymuses were examined 48 h later. As shown in
Table 3, 73% of CD4+CD8+ thymocytes from bcl-x-169
mice were still present 48 h after anti-CD3 treatment, whereas
only 2% of this population remained in nontransgenic ani-
mals. As has been shown by others (2, 39), double-negative
and single-positive thymocyte populations were largely un-
affected by anti-CD3 treatment (Table 3) . Hence, overex-
pression ofBcl-x, can blockanti-CD3-induced apoptosis.
Bcl-xL Fails to Protect Thymocytes from Clonal Deletion In-
duced by Endogenous Superantigens. An important form of
thymocyte apoptosis is the deletion of developing T cells
that express high-affinity TCRs for self-antigens (2, 3) .
Signaling through CD3 in CD4+CD8+ is thought to trans-
duce signals that mimic those of negative selection, and
Bcl-x, is able to block anti-CD3-induced apoptosis. There-
fore we determined the ability of the bcl-x, transgene to
overcome the deletion of self-reactive T cells. We evalu-
ated the deletion of T cells reactive with superantigen Mls-1
bcl-xL Expression Is Regulated in the Thymus and Blocks Apoptosis
Figure 5.
￿
Overexpression of BC'-x1 blocks
thymocyte dexamethasone-induced cell death
in vivo. Transgenic bcl-x-169 mice (C and F)
and control littermates (B and E) were in-
jected i.p. with 2 mg of dexamethasone and
compared with control mice injected with
PBS (A and D). 48 h later, thymocytes (A-C)
were recovered and stained with FITC-con-
jugated anti-CD4 and PE-conjugated anti-
CD8 antibodies and analyzed by flow cytoin-
etry. The mean percentage of cells is given for
each subpopulation. Bone marrow cells (D-
F) were collected at the same time and stained
with FITC-conjugated anti-IgM and biotiny-
lated anti-B220 antibodies. Pro- and pre-B
cells (IgM-132201-) were gated in region IM
(defined by the small rectangle in D-F) . The
percentage of this population is indicated.
The same experiment was repeated twice
with three mice in each experiment with sim-
ilar results. Identical results were obtained
with mice from bcl-x-86 (data not shown).Table 3 .
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and an endogenous superantigen presented in the context
of the MHC class II molecule I-E. When Mls-1 is ex-
pressed in the thymus, T cells bearing TCRs containing
V(36+ , VP7+, V[38 .1 + , or V(39+ regions are deleted (40-
43). Similarly, expression of a specific superantigen in asso-
ciation with I-E induces the deletion of T cells bearing
V[311 + , V[35+ , or V(317a+ regions (44, 45) . Transgenic
mice in the C57BL/6 X SJL (H-2b) background that do
bcl-x-169 Transgenic mice
￿
Control littermates
*Transgenic and control litter-mates were injected with 100 Wg ofanti-CD3 (clone 145-2C11) or 100 N,g ofanti-DNP (clone UC8-1139) i.p. as con-
trol and killed 48 h later. Results were obtained by three-color flow cytometric analysis ofthymocytes simultaneously labeled with FITC-conjugated
anti-CD4, PE-conjugated anti-CD8, and biotinylated anti-CD3 antibodies. Values shown represent the mean ± SD for six animals.
*Differences between control- and anti-CD3-treated cells were statistically significant (p <0.01) as assessed by Student's t test.
Table 4.
￿
Overexpression ofbcl-x, Does Not Block Clonal Deletion Induced by MS- 1° or I-E
1979
￿
Grillot et al.
not express Mls-1 or I-E were crossed to CBA/J mice that
are homozygous for Mls-1 and I-E. Flow cytometric analy-
sis revealed that mature thymocytes expressing V[36 or
V[311 in their TCRs were completely deleted in [CBA/J X
(C57BL/6 X SJL)-bcl-x-169]F1 mice (Table 4) . There was
a compensatory increase in thymocytes bearing V[32+ in
[CBA/J X (136 X SJL)] F1 compared with B6 X SJL mice,
which has been reported previously by others (46) . Consis-
*Results were obtained by three-color flow cytometric analysis of thymocytes simultaneously labeled with biotinylated anti-CD4, PE-conjugated
anti-CD8, and different FITC-conjugated anti-V(3 antibodies. Values shown represent the mean ± SD for five animals. Percentage differences be-
tween bcl-x-169-transgenic and control littermates were not statistically different by Student's t test.
Mice bcl-x tg Mls-la
Percentage of V[36+ in thymocyte populations
CD4+ CD8+ CD4+CD8+
[CBA/J X (B6 X SJL)] + + 0.2±0.0* 0.2±0.0 5.1±0.1
[CBA/J X (136 X SJL)] - + 0.3±0.0 0.0±0.0 4.6±0.2
136 X SJL - - 7.6 - ! - 0.2 9.4±1 .0 4.3±0.3
Percentage ofV[311+ in thymocyte populations
Mice bcl-x tg I-E CD4+ CD8+ CD4+CD8+
[CBA/J X (B6 X SJL)] + + 0.0 ± 0.0 0.3 ± 0.3 5.1 ± 0.3
[CBA/J X (136 X SJL)] - + 0.1±0.0 0.3±0.0 5.5±0.1
B6 X SJL - - 5 .1±0.6 6.6±0.5 4.7 -±0.3
Percentage ofV[32+ in thymocyte populations
Mice bcl-x tg CD4+ CD8+ CD4+CD8+
[CBA/J X (136 X SJL)] + 11 .4±0.5 15 .5±1 .2 3.3 -}0.4
[CBA/J X (B6 X SJL)] - 11 .9 ± 0.8 20.3 ± 1 .1 3.1 ± 0.5
B6XSJL - 3 .8 ± 0.2 3.5 ± 0.1 2.5 ± 0.2
Cell populations Control* Anti-CD3* Control Anti-CD3
X 106
Total cells 61 .0 ± 8.0$ 48.0 ± 6.0$ 40.0 1- 5.0$ 9.0 ± 2.0$
CD4-CD8- 2.8±0.8 3.0±0.2 1 .6±0.7 2.0±0.5
CD4+CD8+ 48.8 ± 4.3$ 35.6 ±- 5.4$ 34.5 ± 2.0$ 0.7 -} 0.1$
CD4+CD8- 4.9 -} 0.5 4.5 ±- 0.3 2.6 -± 0.8 3.8 ± 0.5
CD4-CD8+ 3.2±0.8 3.4±0.3 1 .1±0.2 0.8±0.3Table 5 .
￿
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* bcl-x-169-transgenic mice and control littermates were [C57BL/6 H-Y tg X (C57BL/6 X SJL)1F1 males.
$Results were obtained by two-color flow cytometric analysis o£ thymocytes simultaneously labeled with FITC-conjugated anti-CD4 and PE-conju-
gated anti-CD8 antibodies. Values shown represent the mean ± SD for five animals. Percentage differences between transgenic and control litter-
mates were not statistically significant as determined by Student's t test.
tent with the previous results, peripheral T cells bearing
V(36 or V(311 were similarly deleted in transgenic and con-
trol littermates (data not shown). Thus, constitutive expres-
sion of bcl-xL during T cell development fails to abrogate
clonal deletion induced by Mls-1 or endogenous superanti-
gen in the context of I-E MHC.
Bcl-xL Does Not Block Thymocyte Clonal Deletion Induced
by H- Y Antigen. Because presentation of superantigens to
T cells differs from that of classical peptides (47), the ability
of Bcl-x, to inhibit clonal deletion of reactive T cells spe-
cific to the male H-Y antigen presented in the context of
H-2 Db MHC class 1 molecules (30, 48) was assessed by
mating C57BL/6 mice homozygous for a H-Y ct/P-TCR
transgene (30) to heterozygous bcl-x-169-transgenic mice.
In the H-Y male offspring, CD4+CD8+ and CD4 -CD8+
thymocytes from both bcl-x, and non-bcl-xLtransgenic
mice were markedly deleted, compared with those from
non-H-Y C57BL/6 male mice (Table 5) . The number of
CD4+-CD8- thymocytes from both types of H-Y TCR-
transgenic mice was essentially identical to that of non-
transgenic controls, since clonal deletion induced by H-Y
antigen is restricted to MHC class I molecules (30, 48) .
Thus, Bcl-xL fails to abrogate clonal deletion of T cells re-
active to self- H-Y antigen.
Discussion
These studies demonstrated that bcl-x, can inhibit several
forms of T cell death in thymocytes and/or peripheral T
cells. These include the spontaneous apoptosis in the ab-
sence of growth factors in vitro and the apoptosis induced
by glucocorticoids, y irradiation, calcium ionophore, and
anti-CD3 antibody. All of these stimuli have been shown
to induce apoptotic cell death in thymocytes (13, 14) . We
also showed that endogenous Bcl-x, expression is regulated
during T cell development in a pattern different from that
ofBcl-2. A major role for bcl-x in thymocyte development
has been demonstrated in chimeric mice that are deficient
in Bcl-x (29) . In these studies, the absence ofBcl-x, prefer-
entially affected immature populations of thymocytes and
1980
pre-13 cells (29) . Our results provide an explanation for the
findings in the T cell lineage in that Bcl-x, was expressed
predominately in CD4+ CD8+ thymocytes, the develop-
mental stage particularly affected by the absence of Bcl-x
(29). Deregulated Bcl-x, expression led to a perturbation of
T cell homeostasis characterized by accumulation of thy-
mocytes and mature CD4+ and CD8+ T cells in all lym-
phoid organs. Remarkably, despite this alteration, BC'-xL
deregulation failed to inhibit clonal deletion ofself-reactive
T cells against endogenous superantigens and H-Y antigen.
The basis for the failure or poor ability of Bcl-x, and
Bcl-2 to block clonal deletion compared with T cell death
induced by other stimuli, including anti-CD3, is unclear.
During negative selection, thymocytes bearing TCRs with
high affinity for a self-antigen are deleted (6) . Signaling
through CD3 in CD4+CD8+ cells is thought to transduce
signals that mimic those of negative selection. However,
clonal deletion of thymocytes appears to involve CD4-
CD8, CD28, and other cellular interactions in addition to
the CD3-TCR complex (49, 50) . Thus, it is possible that
self-peptide-MHC/TCR signaling during negative selec-
tion results in a powerful death signal that cannot be abro-
gated by the levels of Bcl-2 or Bcl-xL produced by the
transgenes. It is also possible that certain signaling pathways
such as those responsible for clonal deletion involve distinct
death effector molecules that may not be inhibited by Bcl-2
or Bcl-XL. Experimental evidence for different intracellular
mediators of T cell death has been recently provided for
glucocorticoids, radiation, and TCR-CD3 engagement
(9) . For example, thymocyte apoptosis triggered by expo-
sure to y irradiation or certain DNA-damaging agents but
not glucocorticoids requires the tumor suppressor protein
p53 (51, 52) . Another example is the requirement of nur77
for TCR-mediated apoptosis, whereas it does not play a
role in either glucocorticoid- or radiation-induced death
(53, 54) .
Constitutive expression of bcl-2 and bcl-x, protected thy-
mocytes from a number of apoptotic stimuli. However, in
contrast to our results with bcl-x, mice, a ENt-bcl-2 trans-
gene targeted to the thymus did not result in increased
numbers of thymocytes or peripheral T cells despite ade-
bcl-xL Expression Is Regulated in the Thymus and Blocks Apoptosis
H-Y
Mice*
Bcl-x,. Total
X 106
CD4-CD8-
Thymocyte populations
CD4+CD8+
%,
CD4- CD8+ CD4+CD8 -
+ + 9.0 ± 1 .0t 73.0 ± 9.0 1 ± 0.9 0.8 ± 0.3 15 .9 ± 2.3
+ - 10.0 ± 2.0 70 .0 ± 9.7 5 ± 2.4 0.6 ± 0.3 16.6 ± 3.0
_ - 40.0 ± 8.0 8 .0 ± 0.5 85 ± 8.0 3.1 ± 0.2 4.0 ± 0.2quate expression of Bcl-2 in the thymus and peripheral
lymphoid organs (14) . The reason for the altered T cell ho-
meostasis in Eli-bd-xLtransgenic mice as opposed to the
lack of effect observed in Ela,-bd-2 mice is unclear. How-
ever, mice that are transgenic for a construct containing
bd-2 downstream of the proximal promoter of the lck ty-
rosine kinase gene (lckPr) showed an accumulation of T
cells (mainly CD8+) (13), suggesting that both bcl-x and
bcl-2 can affect T cell homeostasis. Nevertheless, given the
different phenotype observed between EIA,-bcl-x and ElL-
bcl-2-transgenic mice, it can not be excluded that Bcl-x, is
more effective than Bcl-2 in countering some forms of T
cell death operating in vivo. For example, BCl_XL has been
shown to be more efficient than Bcl-2 in protecting the
immature B cell line WEHI 231 from apoptosis induced by
certain chemotherapeutic agents (55) .
Bcl-2 and Bcl-xL display a discordant expression pattern
during T cell development. BCl_XL is primarily expressed in
CD4+CD8+ thymocytes, downregulated in CD4+CD8-
and CD4-CD8+ thymocytes, and undetectable in mature
T cells. In contrast, Bcl-2 is expressed at high levels in early
CD4-CD8- T cell precursors, medullary CD4+CD8 - and
CD4-CD8+ thymocytes and peripheral T cells, but down-
regulated in cortical CD4+ CD8+ thymocytes (15-18) . Af-
ter the submission of this manuscript, another study was
published (56) that showed that BCl_XL is primarily ex-
pressed by CD4+CD8+ thymocytes and confirmed the es-
sential role of bcl-x during thymic development (29). BCI-xL
can protect thymocytes from various apoptotic stimuli. In-
deed, our results have shown that constitutive expression of
Bcl-x, resulted in an accumulation of thymocytes belong-
ing to all major subsets and mature T cells in the periphery.
Thus, it is likely that its expression serves to maintain
CD4+CD8+ thymocytes before positive selection. Because
Bcl-x, is downregulated in more mature single-positive
thymocytes and mature T cells, we suggest that CD4+CD8+
thymocytes that are not positively selected downregulate
BCl_XL later in development and fail to upregulate Bcl-2. In
contrast, the subpopulation of CD4+CD8+ thymocytes
that undergo positive selection is known to upregulate Bcl-2,
a survival signal associated with positive selection (19-22).
Thus, these results suggest that Bcl-2 acts later in develop-
ment than Bcl-xL and functions as a survival switch for CD4+-
CD8 + thymocytes during positive selection.
Diminished BcI-2 expression in cortical CD4+CD8+
thymocytes has been proposed to play a facilitating role in
the death of thymocytes during clonal selection (16-18,
57) . Indeed, CD4+CD8 + thymocytes are more sensitive to
multiple forms of apoptosis, including those induced by
glucocorticoids, y irradiation, and anti-CD3 signaling, than
other thymocyte populations that express BcI-2 (18, 39,
58) . Given that overexpression of Bcl-x, can confer pro-
tection against multiple forms of apoptosis, it is intriguing
that CD4+CD8 + thymocytes are sensitive to apoptosis, de-
spite expression of endogenous Bcl-xL protein. A possible
explanation is that simultaneous expression of Bcl-2 and
BCl_XL is more effective than Bcl-x, or Bcl-2 alone in pro-
tecting thymocytes from apoptosis. An alternative nonex-
clusive interpretation is that the ability of endogenous
Bcl-xL to protect CD4+CD8+ thymocytes from death sig-
nals is countered by intracellular inhibitory proteins. There
is accumulating evidence that the function of Bcl-2 and
BCl_XL is modulated by several interacting proteins that in-
clude Bax (59), Bad (60), and Bag-1 (61). Interestingly,
two proteins of the Bcl-2 family, Bad and Bax, are pro-
duced by thymocytes and can form heterodimers with
Bcl-2 and BCI-xL (60, 62) . In tissue culture experiments,
susceptibility of cells to death signals appears to be deter-
mined by competing dimerizations among the different
proteins ofthe Bcl-2 family expressed by the cell (60) . Fur-
thermore, Bad binds more strongly to BCl_XL than to Bcl-2,
and its interaction with BCl_XL promotes cell death (60) .
Although the precise regulation of Bad or Bax during thy-
mocyte development is unknown, it is tempting to specu-
late that endogenous BCl_XL in CD4+CD8+ is countered
by interacting proteins, resulting in an increased suscepti-
bility to cell death. Based on the present studies and those
by others, we would propose a hypothetical model of T
cell survival in which the threshold to apoptosis is con-
trolled by a balance among survival proteins such as Bcl-2
or Bcl-x,, their inhibitory partners, and the "strength" of
the death signal. In this model, endogenous levels ofBcl-x,
in CD4+CD8+ thymocytes maintain T cell survival but are
not sufficient to protect cells from death signals. Our results
suggest that overexpressed Bcl-xL can effectively compete
for inhibitory proteins or compensate for Bcl-2 downregu-
lation and promotes thymocyte survival.
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